What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Nivolumab plus chemotherapy shows moderate benefit over standard chemotherapy, improving both progression-free survival and overall survival for patients with PD-L1 expression of 1% or more. However, the evidence is primarily based on indirect comparisons with pembrolizumab, leading to some uncertainty regarding the relative effectiveness.
Does the economic case hold at the expected price? — Cost effectiveness
Nivolumab plus chemotherapy is likely cost-effective compared to chemotherapy alone for patients unsuitable for pembrolizumab, with ICER estimates falling below the acceptable threshold of £50,000 per QALY gained. However, it is unlikely to be cost-effective when compared to pembrolizumab.
Is there quality-of-life evidence payers weigh? — Quality of life
The evidence suggests that nivolumab plus chemotherapy maintains quality of life compared to standard chemotherapy, although specific utility values were debated. The clinical experts indicated that the treatment’s benefits in disease control may outweigh the disutilities from treatment-related toxicity.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Nivolumab has a very good safety profile, with mostly mild to moderate adverse events reported. The committee noted that while there are treatment-related toxicities, they are manageable and do not significantly undermine the overall benefit of the treatment.
Was the drug compared against what payers expect? — Comparator Selection
The primary comparator is chemotherapy, which is appropriate; however, the indirect comparison with pembrolizumab introduces uncertainty. The committee acknowledged that while pembrolizumab is a relevant comparator, its uptake has been slower than expected, complicating the assessment.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population is broadly representative of the intended patient population, particularly those with PD-L1 expression of 1% or more. Subgroup analyses were conducted, although there are some limitations regarding the generalizability of results to all patients.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Nivolumab can be integrated into existing treatment pathways with minor adjustments, particularly regarding PD-L1 testing. The committee emphasized the importance of concurrent testing for nivolumab and pembrolizumab to minimize delays in treatment access.
Are the wider system costs understood? — Resource Use and Cost Implications
The resource implications of nivolumab are manageable, particularly when considering its cost-effectiveness compared to chemotherapy. The committee noted that the treatment is likely to be a sustainable option within the Healthcare budget.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is supported by a well-conducted randomized controlled trial (CheckMate 648) and a robust economic model. However, the reliance on indirect comparisons introduces some limitations in the overall robustness of the evidence.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there are uncertainties regarding the indirect comparisons and cost-effectiveness estimates, the overall context of unmet need and the potential benefits of nivolumab support its use. The committee acknowledged the importance of addressing these uncertainties in future evaluations.
